Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP/PS1 mouse model

GLIA

Volumn 64, Issue 2, 2016, Pages 240-254

  Qiao, Jinping ^a,b,c   Wang, Junhui ^a,d   Wang, Hongxing ^e   Zhang, Yanbo ^f   Zhu, Shenghua ^c   Adilijiang, Abulimiti ^d   Guo, Huining ^d   Zhang, Ruiguo ^g   Guo, Wei ^e   Luo, Gang ^h   Qiu, Yiqing ⁱ   Xu, Haiyun ^a   Kong, Jiming ^c   Huang, Qingjun ^a   Li, Xin Min ^d  

^a SHANDONG MENTAL HEALTH CENTER   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f UNIVERSITY OF SASKATCHEWAN   (Canada)

^g FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^h HENAN UNIVERSITY   (China)

ⁱ SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease (AD); Astrocyte; Astrocyte conditioned medium (ACM); Beta amyloid; Fluoxetine

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; FLUOXETINE; PRESENILIN 1; SEROTONIN 2 RECEPTOR; AMYLOID BETA-PROTEIN (1-42); APP PROTEIN, HUMAN; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN NERVE CELL; CELL ACTIVATION; COGNITIVE DEFECT; CONTROLLED STUDY; DETERIORATION; HIPPOCAMPAL NEURONAL CULTURE; HIPPOCAMPUS; MOUSE; NERVE CELL LESION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; BRAIN; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; MAZE TEST; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PLAQUE, AMYLOID;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ASTROCYTES; BRAIN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FLUOXETINE; HUMANS; MAZE LEARNING; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; PRESENILIN-1; RECEPTORS, SEROTONIN, 5-HT2;

EID: 84953837333     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22926     Document Type: Article

References (54)

1. Avila-Muñoz E, Arias C. 2014. When astrocytes become harmful: Functional and inflammatory responses that contribute to Alzheimer's disease. Ageing Res Rev 18:29-40.
2. Alvarez MI, Rivas L, Lacruz C, Toledano A. 2015. Astroglial cell subtypes in the cerebella of normal adults, elderly adults, and patients with Alzheimer's disease: A histological and immunohistochemical comparison. Glia 63:287-312.
3. Ballas N, Lioy DT, Grunseich C, Mandel G. 2009. Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nat Neurosci 12:311-317.
4. Bettegazzi B, Mihailovich M, Di Cesare A, Consonni A, Macco R, Pelizzoni I, Codazzi F, Grohovaz F, Zacchetti D. 2011. Beta-Secretase activity in rat astrocytes: Translational block of BACE1 and modulation of BACE2 expression. Eur J Neurosci 33:236-243.
5. Bosson A, Boisseau S, Buisson A, Savasta M, Albrieux M. 2015. Disruption of dopaminergic transmission remodels tripartite synapse morphology and astrocytic calcium activity within substantia nigra pars reticulata. Glia 63:673-683.
6. Canas PM, Porciuncula LO, Cunha GM, Silva CG, Machado NJ, Oliveira JM, Oliveira CR, Cunha RA. 2009. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci 29:14741-14751.
7. Chen J, Tan Z, Zeng L, Zhang X, He Y, Gao W, Wu X, Li Y, Bu B, Wang W, Duan S. 2013. Heterosynaptic long-term depression mediated by ATP released from astrocytes. Glia 61:178-191.
8. Chen XQ, Qin LY, Zhang CG, Yang LT, Gao Z, Liu S, Lau LT, Fung YW, Greenberg DA, Yu AC. 2005. Presence of neuroglobin in cultured astrocytes. Glia 50:182-186.
9. Chen Y, Tassone F, Berman RF, Hagerman PJ, Hagerman RJ, Willemsen R, Pessah IN. 2010. Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet 19:196-208.
10. Choi SH, Veeraraghavalu K, Lazarov O, Marler S, Ransohoff RM, Ramirez JM, Sisodia SS. 2008. Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron 59:568-580.
11. Christensen RA, Shtifman A, Allen PD, Lopez JR, Querfurth HW. 2004. Calcium dyshomeostasis in beta-amyloid and tau-bearing skeletal myotubes. J Biol Chem 279:53524-53532.
12. Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa G, Adame A, Pham HM, Holzenberger M, Kelly JW, Masliah E, Dillin A . 2009. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 139:1157-1169.
13. Duan S, Anderson CM, Keung EC, Chen Y, Chen Y, Swanson RA. 2003. P2X7 receptor-mediated release of excitatory amino acids from astrocytes. J Neurosci 3:1320-1328.
14. Figley CR, Stroman PW. 2011. The role(s) of astrocytes and astrocyte activity in neurometabolism, neurovascular coupling, and the production of functional neuroimaging signals. Eur J Neurosci 33:577-588.
15. Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE. 1998. Glial-neuronal interactions in Alzheimer's disease: The potential role of a 'cytokine cycle' in disease progression. Brain Pathol 8:65-72.
16. Group AR, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M. 2008. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65:896-905.
17. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297:353-356.
18. Hartlage-Rübsamen M, Zeitschel U, Apelt J, Gärtner U, Franke H, Stahl T, Günther A, Schliebs R, Penkowa M, Bigl V, Rossner S. 2003. Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. Glia 41:169-179.
19. Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, Bae JY, Kim T, Lee J, Chun H, Park HJ, Lee da Y, Hong J, Kim HY, Oh SJ, Park SJ, Lee H, Yoon BE, Kim Y, Jeong Y, Shim I, Bae YC, Cho J, Kowall NW, Ryu H, Hwang E, Kim D, Lee CJ. 2014. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. Nat Med 20:886-896.
20. Kamphuis W, Kooijman L, Orre M, Stassen O, Pekny M, Hol EM. 2015. GFAP and vimentin deficiency alters gene expression in astrocytes and microglia in wild-type mice and changes the transcriptional response of reactive glia in mouse model for Alzheimer's disease. Glia 63:1036-1056.
21. Kong EK, Peng L, Chen Y, Yu AC, Hertz L. 2002. Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochem Res 27:113-120.
22. Lee JY, Kang SR, Yune TY. 2015. Fluoxetine prevents oligodendrocyte cell death by inhibiting microglia activation after spinal cord injury. J Neurotrauma 32:633-644.
23. Li B, Zhang S, Zhang H, Nu W, Cai L, Hertz L, Peng L. 2008. Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation. Psychopharmacology (Berl) 201:443-458.
24. Liu L, Herukka SK, Minkeviciene R, van Groen T, Tanila H. 2004. Longitudinal observation on CSF Abeta42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice. Neurobiol Dis 17:516-523.
25. Matos M, Augusto E, Machado NJ, dos Santos-Rodrigues A, Cunha RA, Agostinho P. 2012. Astrocytic adenosine A2A receptors control the amyloid-beta peptide-induced decrease of glutamate uptake. J Alzheimers Dis 31:555-567.
26. Mrak RE, Griffin WS. 2005. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26:349-354.
27. Mita S, Schon EA, Herbert J. 1989. Widespread expression of amyloid beta-protein precursor gene in rat brain. Am J Pathol 134:1253-1261.
28. Modrego PJ. 2010. Depression in Alzheimer's disease. Pathophysiology, diagnosis, and treatment. J Alzheimers Dis 21:1077-1087.
29. Mosconi L, Glodzik L, Mistur R, McHugh P, Rich KE, Javier E, Williams S, Pirraglia E, De Santi S, Mehta PD, et al. 2010. Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. Biol Psychiatry 68:913-921.
30. Mostert JP, Koch MW, Heerings M, Heersema DJ, De Keyser J. 2008. Therapeutic potential of fluoxetine in neurological disorders. CNS Neurosci Ther 14:153-164.
31. Mowla A, Mosavinasab M, Haghshenas H, Borhani Haghighi A. 2007. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 27:484-487.
32. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC, Wegiel J. 2004. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 25:663-674.
33. Paradisi S, Sacchetti B, Balduzzi M, Gaudi S, Malchiodi-Albedi F. 2004. Astrocyte modulation of in vitro beta-amyloid neurotoxicity. Glia 46:252-260.
34. Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F, Zhang Z, Wei S, Sun X, Chen CH, et al. 2008. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 205:2781-2789.
35. Scharre DW, Chang SI. 2002. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord 16:128-130.
36. Selkoe DJ. 1996. Cell biology of the beta-amyloid precursor protein and the genetics of Alzheimer's disease. Cold Spring Harb Symp Quant Biol 61:587-596.
37. Seyb KI, Ansar S, Bean J, Michaelis ML. 2006. Beta-Amyloid and endoplasmic reticulum stress responses in primary neurons: Effects of drugs that interact with the cytoskeleton. J Mol Neurosci 28:111-123.
38. Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, Ficker WD, Yan P, Xiong C, Frederiksen C, Grzelak MV, Chott R, Bateman RJ, Morris JC, Mintun MA, Lee JM, Cirrito JR. 2014. An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med 6:236re4
39. Shrivastava AN, Kowalewski JM, Renner M, Bousset L, Koulakoff A, Melki R, Giaume C, Triller A. 2013. Beta-amyloid and ATP-induced diffusional trapping of astrocyte and neuronal metabotropic glutamate type-5 receptors. Glia 61:1673-1686.
40. Storey E, Cappai R. 1999. The amyloid precursor protein of Alzheimer's disease and the Abeta peptide. Neuropathol Appl Neurobiol 25:81-97.
41. Suh YH, Checler F. 2002. Amyloid precursor protein, presenilins, and alpha-synuclein: Molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev 54:469-525.
42. Toledo EM, Inestrosa NC. 2010. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry 15:272-285.
43. Valera E, Ubhi K, Mante M, Rockenstein E, Masliah E. 2014. Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy. Glia 62:317-337.
44. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ. 2000. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 20:1657-1665.
45. Walsh DM, Selkoe DJ. 2004. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44:181-193.
46. Wang J, Zhang Y, Xu H, Zhu S, Wang H, He J, Zhang H, Guo H, Kong J, Huang Q, Li XM. 2014a. Fluoxetine improves behavioral performance by suppressing the production of soluble β-amyloid in APP/PS1 mice. Curr Alzheimer Res 11:672-680. a)
47. Wang J, Zhu S, Wang H, He J, Zhang Y, Adilijiang A, Zhang H, Hartle K, Guo H, Kong J, Huang Q, Li XM. 2014b. Astrocyte-dependent protective effect of quetiapine on GABAergic neuron is associated with the prevention of anxiety-like behaviors in aging mice after long-term treatment. J Neurochem 130:780-789. b)
48. Wang J, Qiao J, Zhang Y, Wang H, Zhu S, Zhang H, Hartle K, Guo H, Guo W, He J, Kong J, Huang Q, Li XM. 2014c. Desvenlafaxine prevents white matter injury and improves the decreased phosphorylation of the rate-limiting enzyme of cholesterol synthesis in a chronic mouse model of depression. J Neurochem 131:229-238. c)
49. Wragg RE, Jeste DV. 1989. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 146:577-587.
50. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J. 2003. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 9:453-457.
51. Xiao L, Xu H, Zhang Y, Wei Z, He J, Jiang W, Li X, Dyck LE, Devon RM, Deng Y, et al. 2008. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry 13:697-708.
52. Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM. 2009. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci 29:10706-10714.
53. Yoon BE, Lee CJ. 2014. GABA as a rising gliotransmitter. Front Neural Circuits 8:141
54. Zhao J, O'Connor T, Vassar R. 2011. The contribution of activated astrocytes to Aβ production: Implications for Alzheimer's disease pathogenesis. J Neuroinflammation 8:150